1. Cellomax Science H1 2025 Performance: What Happened?

Cellomax Science recorded sales of KRW 12.374 billion and operating profit of KRW 2.012 billion in H1 2025. Both sales and operating profit decreased compared to the same period last year, presumedly due to the base effect of special sales in the second half of 2024. While the health functional food sector maintained steady growth, increased selling, general and administrative expenses (SG&A) negatively impacted overall profitability.

2. Analyzing the Profitability Decline: Why These Results?

The primary cause of the decline in operating profit is the increase in SG&A expenses, including advertising and labor costs. While this can be attributed to aggressive marketing and business expansion, it highlights the need for improved cost efficiency. The low operating profit margin (2.01%) suggests intensifying competition in the health functional food market and the urgent need to improve profitability.

3. Future Outlook and Investment Strategy: What Now?

In the short term, growth in the health functional food sector and overseas expansion could act as momentum for the stock price, but improving profitability remains a key variable. In the mid-to-long term, expansion into overseas markets, the success of new businesses, and strengthening product competitiveness through R&D will determine growth.

  • Key Investment Points: Closely monitor improvements in profitability, overseas market entry performance, and progress in new businesses.
  • Investor Action Plan: Make prudent investment decisions based on a comprehensive consideration of both positive and negative factors.

4. Cellomax Science Investment: Key Checklist

Before making an investment decision, thoroughly review the following key questions:

  • What is the company’s strategy for improving profitability?
  • Is the overseas market entry strategy concrete?
  • Is the competitiveness of the new business sufficient?